Strategic Initiative

Slingshot members are tracking this corporate initiative:

Allergan (AGN) and Novartis (NVS) Announce Collaboration for Phase 2b Trial Evaluating AGN's Cenicriviroc with NVS' Farnesoid X Receptor (FXR) in Non-Alcoholic Steatohepatitis (NASH)

Source Link:: https://www.allergan.com/News/News/Thomson-Reuters/Allergan-Expands-Leading-Research-Development-NAS

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

AGN

100%

NVS

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Apr 18, 2017

Projected Implementation:

Q2, 2017

Relevance Tracked Until:

Q2, 2019

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Nash, Non-alcoholic Steatohepatitis, Cenicriviroc, Farnesoid X Receptor, Fxr